ELYM vs. OVID, MACK, GBIO, PBYI, QURE, VERU, HOWL, FHTX, GTHX, and TSVT
Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Ovid Therapeutics (OVID), Merrimack Pharmaceuticals (MACK), Generation Bio (GBIO), Puma Biotechnology (PBYI), uniQure (QURE), Veru (VERU), Werewolf Therapeutics (HOWL), Foghorn Therapeutics (FHTX), G1 Therapeutics (GTHX), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Eliem Therapeutics (NASDAQ:ELYM) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, Ovid Therapeutics had 20 more articles in the media than Eliem Therapeutics. MarketBeat recorded 22 mentions for Ovid Therapeutics and 2 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.69 beat Ovid Therapeutics' score of 0.34 indicating that Eliem Therapeutics is being referred to more favorably in the media.
Eliem Therapeutics has higher earnings, but lower revenue than Ovid Therapeutics.
69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ovid Therapeutics received 336 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
Ovid Therapeutics has a consensus target price of $8.08, suggesting a potential upside of 156.61%. Given Ovid Therapeutics' higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Eliem Therapeutics.
Eliem Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Eliem Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -10,691.14%. Eliem Therapeutics' return on equity of -13.32% beat Ovid Therapeutics' return on equity.
Summary
Ovid Therapeutics beats Eliem Therapeutics on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eliem Therapeutics Competitors List
Related Companies and Tools
